Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Real-world dosing and outcomes 6-month persister loss about 12-13% (Hankosky DOM 2025), broad-cohort about -9.8% (Adamidis Cureus 2026), telehealth completers near -23% (Duncan Obesity Pillars 2026)
.png&w=828&q=100)
Are you sleeping better
The JAMA real-world study comparing semaglutide and tirzepatide outcomes in clinical practice found that tirzepatide was associated with significantly greater weight loss than semaglutide, confirming that the clinical trial advantage holds outside of controlled environments
If needles are a genuine barrier for you, your provider will talk through the tradeoff honestly but you should know you're choosing convenience over certainty
Extended titration protocols spread dose increases across 812 weeks instead of the standard 4-week schedule, giving your thermoregulatory system more time to adapt
